Skip to main content
SpringerLink
Log in

The safe handling of 211At compounds

  • Letter to the Editor
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 26 July 2022

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Watabe T, Hosono M, Kinuya S, Yamada T, Yanagida S, Namba M, et al. Manual on the proper use of sodium astatide ([211At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition). Ann Nucl Med. 2021;35:753–66.

    Article  CAS  Google Scholar 

  2. Watabe T, Kaneda-Nakashima K, Liu Y, Shirakami Y, Ooe K, Toyoshima A, et al. Enhancement of 211At uptake via the sodium iodide symporter by the addition of ascorbic acid in targeted alpha-therapy of thyroid cancer. J Nucl Med. 2019;60:1301–7.

    Article  CAS  Google Scholar 

  3. Lindencrona U, Sillfors-Elverby L, Nilsson M, Forssell-Aronsson E. Adsorption and volatility of free 211At and 125I. Appl Radiat Isot. 2005;62:395–403.

    Article  CAS  Google Scholar 

  4. Ohnuki K, Yoshimoto M, Haba H, Manabe S, Takashima H, Yasunaga M, et al. Protection from contamination by 211At, an enigmatic but promising alpha-particle-emitting radionuclide. EJNMMI Phys. 2022;9:39.

    Article  Google Scholar 

  5. Ohnuki K, Yoshimoto M, Fujii H. Radiological protection and biological COVID-19 protection in the nuclear medicine department. Eur J Nucl Med Mol Imaging. 2021;48:6–8.

    Article  CAS  Google Scholar 

Download references

Funding

This study was supported partially by the National Cancer Center Research and Development Funds 2021-S-3 and 2022-A-10. 211At was supplied by the Supply Platform of Short-lived Radioisotopes, supported by a Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research on Innovative Areas, Grant Number 16H06278.

Author information

Authors and Affiliations

  1. Division of Functional Imaging, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6–5–1 Kashiwanoha, Kashiwa, 277–8577, Japan

    Kazunobu Ohnuki, Mitsuyoshi Yoshimoto & Hirofumi Fujii

  2. Bioplastic Research Team, RIKEN Center for Sustainable Resource Science, 2–1 Hirosawa, Wako, 351–0198, Japan

    Yasumasa Takenaka

Authors
  1. Kazunobu Ohnuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasumasa Takenaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mitsuyoshi Yoshimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hirofumi Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hirofumi Fujii.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ohnuki, K., Takenaka, Y., Yoshimoto, M. et al. The safe handling of 211At compounds. Ann Nucl Med 36, 842–843 (2022). https://doi.org/10.1007/s12149-022-01778-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-022-01778-w

Search

Navigation